Seminars in liver disease最新文献_第9页

This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol. 这就是 MASLD 的样子：多参数磁共振成像方案的潜力。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-28 DOI: 10.1055/a-2334-8525

Anja M Fischer, Nazim Lechea, Harvey O Coxson

{"title":"This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol.","authors":"Anja M Fischer, Nazim Lechea, Harvey O Coxson","doi":"10.1055/a-2334-8525","DOIUrl":"10.1055/a-2334-8525","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with a broad spectrum defined by liver biopsy. This gold standard method evaluates three features: steatosis, activity (ballooning and lobular inflammation), and fibrosis, attributing them to certain grades or stages using a semiquantitative scoring system. However, liver biopsy is subject to numerous restrictions, creating an unmet need for a reliable and reproducible method for MASLD assessment, grading, and staging. Noninvasive imaging modalities, such as magnetic resonance imaging (MRI), offer the potential to assess quantitative liver parameters. This review aims to provide an overview of the available MRI techniques for the three criteria evaluated individually by liver histology. Here, we discuss the possibility of combining multiple MRI parameters to replace liver biopsy with a holistic, multiparametric MRI protocol. In conclusion, the development and implementation of such an approach could significantly improve the diagnosis and management of MASLD, reducing the need for invasive procedures and paving the way for more personalized treatment strategies.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"226-238"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease? 一般人群和肝病患者是否有安全的饮酒限量？

IF 4.2 3区医学

Seminars in liver disease Pub Date : 2024-04-04 DOI: 10.1055/s-0044-1785228

Manuel Romero-Gómez, Juan Pablo Arab, Claudia P. Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller

{"title":"Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?","authors":"Manuel Romero-Gómez, Juan Pablo Arab, Claudia P. Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller","doi":"10.1055/s-0044-1785228","DOIUrl":"https://doi.org/10.1055/s-0044-1785228","url":null,"abstract":"Excessive alcohol consumption represents an important burden for health systems worldwide and is a major cause of liver- and cancer-related deaths. Alcohol consumption is mostly assessed by self-report that often underestimates the amount of drinking. While alcohol use disorders identification test - version C is the most widely used test for alcohol use screening, in patients with liver disease the use of alcohol biomarker could help an objective assessment. The amount of alcohol that leads to significant liver disease depends on gender, genetic background, and coexistence of comorbidities (i.e., metabolic syndrome factors). All patients with alcohol-associated liver disease are recommended to follow complete abstinence and they should be treated within multidisciplinary teams. Abstinence slows down and even reverses the progression of liver fibrosis and can help recompensate patients with complicated cirrhosis. Whether there is a safe amount of alcohol in the general population is a matter of intense debate. Large epidemiological studies showed that the safe amount of alcohol to avoid overall health-related risks is lower than expected even in the general population. Even one drink per day can increase cancer-related death. In patients with any kind of chronic liver disease, especially in those with metabolic-associated steatotic liver disease, no alcohol intake is recommended. This review article discusses the current evidence supporting the deleterious effects of small-to-moderate amounts of alcohol in the general population and in patients with underlying chronic liver disease. ","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"16 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140576443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice. 非酒精性脂肪肝的新命名法：了解代谢功能障碍相关性脂肪肝、代谢功能障碍和酒精相关性肝病及其在临床实践中的意义。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-03-26 DOI: 10.1055/s-0044-1785196

Clémence M Canivet, Jérôme Boursier, Rohit Loomba

{"title":"New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.","authors":"Clémence M Canivet, Jérôme Boursier, Rohit Loomba","doi":"10.1055/s-0044-1785196","DOIUrl":"10.1055/s-0044-1785196","url":null,"abstract":"In June 2023, under the patronage of the American Association for Study of Liver Disease, the European Association for Study of the Liver, and the Asociación Latinoamericana para el Estudio del Hígado with the involvement of 236 participants from around the world, a new nomenclature and definition for nonalcoholic fatty liver disease (NAFLD) has been proposed. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined as presence of hepatic steatosis and at least one of the cardiometabolic risk factors with alcohol intake less than 140 g/wk for women and 210 g/wk for men and no other causes of steatosis. A new entity called combined metabolic dysfunction- and alcohol-associated liver disease (MetALD) was created outside of pure MASLD for patients with metabolic dysfunction and alcohol intake greater than that allowed for MASLD (i.e., 140-350 g/wk for women and 210-420 g/wk for men). Recent studies have confirmed a 95% overlap between NAFLD and the new MASLD diagnostic criteria. Natural history, biomarkers, and thresholds of alcohol intake in MetALD group remains to be studied and validated.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"35-42"},"PeriodicalIF":3.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. 肝细胞癌肝移植：叙事回顾与未来展望。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-01-11 DOI: 10.1055/a-2242-7543

Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar

{"title":"Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future.","authors":"Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar","doi":"10.1055/a-2242-7543","DOIUrl":"10.1055/a-2242-7543","url":null,"abstract":"Liver transplantation (LT) is a highly effective treatment for carefully selected patients with hepatocellular carcinoma (HCC). In this review, we explored the development of LT selection criteria and organ allocation policies, comparing original data to underscore their historical progression into the intricate task of quantitatively estimating pre- and post-LT survivals. We emphasized the role of biomarkers such as serum alpha-fetoprotein, Des-gamma-carboxy-prothrombin, circulating tumor cells, and circulating tumor DNA in predicting patient outcomes. Additionally, we examined the transplant-associated survival benefits and the difficulties in accurately calculating these benefits. We also reviewed recent advancements in targeted therapy and checkpoint inhibitors for advanced, inoperable HCC and projected their integration into LT for HCC. We further discussed the growing use of living donor liver transplants in the United States and compared its outcomes with those of deceased donor liver transplants. Furthermore, we examined the progress in machine perfusion techniques, which have shown potential in improving patient outcomes and enlarging the donor pool. These advancements present opportunities to enhance LT patient survivals, refine selection criteria, establish new priority metrics, develop innovative bridging and downstaging strategies, and formulate redesigned LT strategies for HCC treatments.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"79-98"},"PeriodicalIF":3.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis. 治疗药物性肝病的 UDCA：临床和病理生理学基础。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-02-20 DOI: 10.1055/s-0044-1779520

Fernando Bessone, Geraldine L Hillotte, Natalia Ahumada, Fernanda Jaureguizahar, Anabela C Medeot, Marcelo G Roma

{"title":"UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis.","authors":"Fernando Bessone, Geraldine L Hillotte, Natalia Ahumada, Fernanda Jaureguizahar, Anabela C Medeot, Marcelo G Roma","doi":"10.1055/s-0044-1779520","DOIUrl":"10.1055/s-0044-1779520","url":null,"abstract":"Drug-induced liver injury (DILI) is an adverse reaction to medications and other xenobiotics that leads to liver dysfunction. Based on differential clinical patterns of injury, DILI is classified into hepatocellular, cholestatic, and mixed types; although hepatocellular DILI is associated with inflammation, necrosis, and apoptosis, cholestatic DILI is associated with bile plugs and bile duct paucity. Ursodeoxycholic acid (UDCA) has been empirically used as a supportive drug mainly in cholestatic DILI, but both curative and prophylactic beneficial effects have been observed for hepatocellular DILI as well, according to preliminary clinical studies. This could reflect the fact that UDCA has a plethora of beneficial effects potentially useful to treat the wide range of injuries with different etiologies and pathomechanisms occurring in both types of DILI, including anticholestatic, antioxidant, anti-inflammatory, antiapoptotic, antinecrotic, mitoprotective, endoplasmic reticulum stress alleviating, and immunomodulatory properties. In this review, a revision of the literature has been performed to evaluate the efficacy of UDCA across the whole DILI spectrum, and these findings were associated with the multiple mechanisms of UDCA hepatoprotection. This should help better rationalize and systematize the use of this versatile and safe hepatoprotector in each type of DILI scenarios.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"1-22"},"PeriodicalIF":3.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. 为 MASLD 患者量身定制的护理模式。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-01-25 DOI: 10.1055/a-2253-9181

Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab

{"title":"Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab","doi":"10.1055/a-2253-9181","DOIUrl":"10.1055/a-2253-9181","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a health care challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the health care system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care (MoC), including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed MoC.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"54-68"},"PeriodicalIF":3.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. 更正：肝细胞癌肝移植：叙事回顾与未来一瞥》。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-06-05 DOI: 10.1055/s-0044-1787737

Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar

引用次数: 0

Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting. 基层医疗机构早期检测隐匿性肝纤维化的算法。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-01-23 DOI: 10.1055/s-0043-1778127

Katrine Tholstrup Bech, Katrine Prier Lindvig, Maja Thiele, Laurent Castera

引用次数: 0

Gestational and Developmental Contributors of Pediatric MASLD. 小儿 MASLD 的妊娠和发育因素。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-02-29 DOI: 10.1055/s-0044-1782210

Marialena Mouzaki, Jessica G Woo, Senad Divanovic

引用次数: 0

GAS6/TAM Axis as Therapeutic Target in Liver Diseases. 作为肝病治疗靶点的 GAS6/TAM 轴。

IF 3.7 3区医学

Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-02-23 DOI: 10.1055/a-2275-0408

Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí

{"title":"GAS6/TAM Axis as Therapeutic Target in Liver Diseases.","authors":"Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí","doi":"10.1055/a-2275-0408","DOIUrl":"10.1055/a-2275-0408","url":null,"abstract":"TAM (TYRO3, AXL, and MERTK) protein tyrosine kinase membrane receptors and their vitamin K-dependent ligands GAS6 and protein S (PROS) are well-known players in tumor biology and autoimmune diseases. In contrast, TAM regulation of fibrogenesis and the inflammation mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and, ultimately, liver cancer has recently been revealed. GAS6 and PROS binding to phosphatidylserine exposed in outer membranes of apoptotic cells links TAMs, particularly MERTK, with hepatocellular damage. In addition, AXL and MERTK regulate the development of liver fibrosis and inflammation in chronic liver diseases. Acute hepatic injury is also mediated by the TAM system, as recent data regarding acetaminophen toxicity and acute-on-chronic liver failure have uncovered. Soluble TAM-related proteins, mainly released from activated macrophages and hepatic stellate cells after hepatic deterioration, are proposed as early serum markers for disease progression. In conclusion, the TAM system is becoming an interesting pharmacological target in liver pathology and a focus of future biomedical research in this field.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"99-114"},"PeriodicalIF":3.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139940678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0